(E)-3-[2-[(E)-3-[4-(2-aminoethoxy)-3-methoxyphenyl]prop-1-enyl]phenyl]prop-2-enoic acid | 1394015-33-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-3-[2-[(E)-3-[4-(2-aminoethoxy)-3-methoxyphenyl]prop-1-enyl]phenyl]prop-2-enoic acid
• CAS: 1394015-33-8
• 化学式: C₂₁H₂₃NO₄
• 分子量: 353.418
• InChiKey: XPPKVTJXPOVBAM-URFQIUESSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  81.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  异硫氰酸荧光素酯 、 (E)-3-[2-[(E)-3-[4-(2-aminoethoxy)-3-methoxyphenyl]prop-1-enyl]phenyl]prop-2-enoic acid 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 以270 mg的产率得到5-[2-[4-[(E)-3-[2-[(E)-2-carboxyethenyl]phenyl]prop-2-enyl]-2-methoxyphenoxy]ethylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid
  参考文献：
  名称：

  Fluorescent Human EP₃ Receptor Antagonists

  摘要：

  Exchange of the lipophilc part of ortho-substituted cinnamic acid lead structures with different small molecule fluorophoric moieties via a dimethylene spacer resulted in hEP(3)R ligands with affinities in the nanomolar concentration range. Synthesized compounds emit fluorescence in the blue, green, and red range of light and have been tested concerning their potential as a pharmacological tool. hEP(3)Rs were visualized by confocal laser scanning microscopy on HT-29 cells, on murine kidney tissues, and on human brain tissues and functionally were characterized as antagonists on human platelets. Inhibition of PGE(2) and collagen-induced platelet aggregation was measured after preincubation with novel hEP(3)R ligands. The pyryllium-labeled ligand 8 has been shown as one of the most promising structures, displaying a useful fluorescence and highly affine hEP(3)R antagonists.

  DOI：

  10.1021/ml300191g
• 作为产物：
  描述：

  丁香酚 在 盐酸 、 lithium acetate 、 四丁基氯化铵 、 水 、 palladium diacetate 、 三苯基膦 、 lithium chloride 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (E)-3-[2-[(E)-3-[4-(2-aminoethoxy)-3-methoxyphenyl]prop-1-enyl]phenyl]prop-2-enoic acid
  参考文献：
  名称：

  Fluorescent Human EP₃ Receptor Antagonists

  摘要：

  Exchange of the lipophilc part of ortho-substituted cinnamic acid lead structures with different small molecule fluorophoric moieties via a dimethylene spacer resulted in hEP(3)R ligands with affinities in the nanomolar concentration range. Synthesized compounds emit fluorescence in the blue, green, and red range of light and have been tested concerning their potential as a pharmacological tool. hEP(3)Rs were visualized by confocal laser scanning microscopy on HT-29 cells, on murine kidney tissues, and on human brain tissues and functionally were characterized as antagonists on human platelets. Inhibition of PGE(2) and collagen-induced platelet aggregation was measured after preincubation with novel hEP(3)R ligands. The pyryllium-labeled ligand 8 has been shown as one of the most promising structures, displaying a useful fluorescence and highly affine hEP(3)R antagonists.

  DOI：

  10.1021/ml300191g

文献信息

• Fluorescent Human EP₃ Receptor Antagonists
  作者：Miriam Tomasch、J. Stephan Schwed、Karina Kuczka、Sascha Meyer dos Santos、Sebastian Harder、Rolf M. Nüsing、Alexander Paulke、Holger Stark

  DOI：10.1021/ml300191g

  日期：2012.9.13

  Exchange of the lipophilc part of ortho-substituted cinnamic acid lead structures with different small molecule fluorophoric moieties via a dimethylene spacer resulted in hEP(3)R ligands with affinities in the nanomolar concentration range. Synthesized compounds emit fluorescence in the blue, green, and red range of light and have been tested concerning their potential as a pharmacological tool. hEP(3)Rs were visualized by confocal laser scanning microscopy on HT-29 cells, on murine kidney tissues, and on human brain tissues and functionally were characterized as antagonists on human platelets. Inhibition of PGE(2) and collagen-induced platelet aggregation was measured after preincubation with novel hEP(3)R ligands. The pyryllium-labeled ligand 8 has been shown as one of the most promising structures, displaying a useful fluorescence and highly affine hEP(3)R antagonists.